葛兰素史克新任CEO寻求20亿至40亿美元“显而易见”的交易机会。
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
生物技术与制药领域的最新动态
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
FDA demands better response from Abbott over Libre inspection violations
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
Pharosai and 10X Genomics Partner to Transform Cancer Research with Ai and Spatial Biology - marketscreener.com
Illumina Wildlife Genomics Deal Highlights New Conservation And Valuation Story - simplywall.st
Thermo Fisher to Close Franklin, Mass. Site, Cut Up to 80 Jobs - Contract Pharma
GSK’s new CEO eyes more dealmaking, intense pipeline inspection
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Agilent Technologies Inc. Showcases Next-Generation Automated Solutions at SLAS2026 - marketscreener.com
Veradermics lands $256M IPO for oral Rogaine
Midi Health raises $100M as it plans expansion into urgent care, research
Hims adds Grail's cancer test amid questions about widespread use
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology - Yahoo Finance
Why TrumpRx is stumbling before it gets off the ground
First-in-class fusion protein reverses T-cell exhaustion across multiple models
STK-026: a next-generation IL-12 therapy with improved safety profile
TGR5 as a target for acute kidney injury
A humanized mouse mimics Fcγ receptor biology in antibody essays